Oxford Immunotec sees Q4 top line of ~$25M, shy of consensus; shares down 15%

|About: Oxford Immunotec Globa... (OXFD)|By:, SA News Editor

Thinly traded micro cap Oxford Immunotec (OXFD -14.7%) slumps on a 4x surge in volume on the heels of its announcement of preliminary results for Q4 2017 and full-year.

Management expects revenue in the final quarter and full-year 2017 to be $24.9M - 25.4M and $103.0M - 104.5M, respectively. Consensus views for the quarter and year are $26.1M and $104.1M, respectively.

Final results will be released on Tuesday, February 27 before the open. The company will provide its 2018 outlook at that time.


Subscribe for full text news in your inbox